Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

On Tuesday, Cellectar Biosciences, Inc. CLRB unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets cancer.Due to recent communications with the FDA regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the company has decided to pursue strategic options for the further development and commercialization of this product candidate.Also Read: Cancer-Focused Cellec ...